GTS Securities’s Amplify Weight Loss Drug & Treatment ETF THNR Stock Holding History

GTS Securities’s Portfolio THNR Stock Details THNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$240K	Buy	+9,761	New	+$249K	0.01%	1243
2025 Q2	–	Sell	-33,373	Closed	-$719K	–	1669
2025 Q1	$719K	Buy	33,373 +8,506	+34%	+$194K	0.03%	526
2024 Q4	$561K	Buy	24,867 +12,127	+95%	+$300K	0.03%	561
2024 Q3	$341K	Buy	+12,740	New	+$342K	﹤0.01%	3186

Other funds holding THNR

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GFA

Godfrey Financial Associates Glenmont, New York $117M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GTS Securities's THNR Position: Q1 2026 in Review

GTS Securities opened a new position in Amplify Weight Loss Drug & Treatment ETF (THNR) in Q1 2026: 9,761 shares worth $240K. The stake represents 0.01% of the portfolio and ranks #1243 among its holdings. This is a return to the name: GTS Securities previously reported a position in THNR as recently as Q1 2025.

GTS Securities first reported a position in THNR in Q3 2024 and has held it in 4 quarters since. The position peaked at $719K in Q1 2025. 4 funds tracked by Wall St. Rank hold THNR as of Q1 2026.

GTS Securities held 9,761 shares of Amplify Weight Loss Drug & Treatment ETF worth $240K as of Q1 2026.
Amplify Weight Loss Drug & Treatment ETF was a new GTS Securities position in Q1 2026.
Amplify Weight Loss Drug & Treatment ETF made up 0.01% of GTS Securities's portfolio in Q1 2026, its #1243 holding.
GTS Securities first reported a position in Amplify Weight Loss Drug & Treatment ETF in Q3 2024 and has held it in 4 quarters since.
GTS Securities's Amplify Weight Loss Drug & Treatment ETF position peaked at $719K in Q1 2025.
4 funds tracked by Wall St. Rank held Amplify Weight Loss Drug & Treatment ETF as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.